PATENT CLAIM ANALYSIS

Application Number: 15770824
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-12
Patent Classification: ["549", "406000"]

Abstract:
The present invention provides novel heterocyclic compounds as anticancer agents, especially as estrogen receptor (ER) antagonists/degraders and process for their preparation.

Claim (Index 4):
The compound of  claim 1  wherein R 9  is hydrogen or C 1-3  alkyl and R 10  is selected from C 1-15  linear or branched alkyl optionally interrupted with one or more radicals selected from \u2014O\u2014, \u2014NR 5 \u2014, \u2014S\u2014 and \u2014CR 5 \u2550CR 5 \u2014.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 91.0
- Lexical Diversity: 1.04167
- Patent Class: 549.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14900425', '15103215', '14968405', '11268374', '10758675']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7632637859663415
- 35 USC 102 Novelty (BERT): 0.5124896651009951
- Combined Prediction Score: 0.7381863738798068
- Mean Citation Score: 288.6774440000001
- Max Citation Score: 291.9329
- Similarity Product: 212.9352943450272

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test